#27Healing, Repair & Immune
ARA-290
innate-repair-receptor peptide agonist
Evidence: human RCTReviewed 2026-07-25
Investigated uses
- Small-fiber neuropathy and inflammatory/tissue-repair conditions.
Mechanism and hypotheses
- ARA-290/cibinetide is designed to activate the innate repair receptor, a heteromer involving the erythropoietin receptor and beta-common receptor, without conventional erythropoietic activity.
- Hypothesized: Neuroprotective and anti-inflammatory effects remain indication-specific hypotheses supported by small trials and preclinical work.
Human evidence
- Small randomized studies in sarcoidosis-associated small-fiber neuropathy reported symptom and corneal-nerve signals. Limitations: Small samples, short duration and disease-specific endpoints; no approved formulation.
Safety highlights
- Unknown or insufficiently characterized for the exact catalog product.
- Identity, purity, sterility, endotoxin, aggregation, immunogenicity, concentration and route-specific risks are not adequately characterized.
Regulatory context
No FDA-approved product matching the exact catalog presentation was identified in this review.
Sources used for this entry
- PubMed search: ARA-290 — PubMed
- Drugs@FDA database — U.S. Food and Drug Administration
- EMA medicines search — European Medicines Agency
- NCT02039687: Cibinetide in sarcoidosis small-fiber neuropathy — ClinicalTrials.gov
- ARA 290 improves symptoms in sarcoidosis-associated small fiber neuropathy — Molecular Medicine / PubMed